Evaluation of Biological Biomarkers Diagnostic of Toxoplasmosis Uveitis
Keywords
Abstract
Dates
Last Verified: | 06/30/2016 |
First Submitted: | 07/20/2016 |
Estimated Enrollment Submitted: | 07/21/2016 |
First Posted: | 07/24/2016 |
Last Update Submitted: | 07/21/2016 |
Last Update Posted: | 07/24/2016 |
Actual Study Start Date: | 12/31/2009 |
Estimated Primary Completion Date: | 12/31/2015 |
Estimated Study Completion Date: | 12/31/2015 |
Condition or disease
Intervention/treatment
Other: Subjects suspected of toxoplasmosis chorioretinitis infection
Other: Subjects suspected of toxoplasmosis chorioretinitis infection
Biological: Subjects suspected of toxoplasmosis chorioretinitis infection
Drug: Subjects suspected of toxoplasmosis chorioretinitis infection
Drug: Subjects suspected of toxoplasmosis chorioretinitis infection
Other: Subjects suspected of toxoplasmosis chorioretinitis infection
Phase
Arm Groups
Arm | Intervention/treatment |
---|---|
Other: Subjects suspected of toxoplasmosis chorioretinitis infection Subjects clinically suspected at least of one active source of toxoplasmosis chorioretinitis infection | Other: Subjects suspected of toxoplasmosis chorioretinitis infection |
Eligibility Criteria
Sexes Eligible for Study | All |
Accepts Healthy Volunteers | Yes |
Criteria | Inclusion Criteria: - Age over 18 years - Subjects clinically suspected at least of one active source of toxoplasmosis chorioretinitis infection - Persons affiliated to national social security Exclusion Criteria: - Pregnant, parturient or breastfeeding women - Persons deprived of liberty by judicial or administrative decision, person under legal protection - Refusal by a patient to do the PCA (anterior chamber puncture) - Patients whose following will be difficult or nonexistent |
Outcome
Primary Outcome Measures
1. ELISA tests [About an hour]